Genasys reported a Q3 2026 revenue drop to $7.3M due to supply-chain issues and a work suspension, not demand loss. Despite this, gross margin improved to 57.1% and operating loss narrowed to $4M, showing better efficiency. An analyst raised the price target to $3.60, implying a 108% upside from $1.73. With supply issues resolved and operations resumed, management expects 2026 to be a record year for revenue and profits, supported by a strong order backlog and growing business pipeline.
Industrial Alliance Securities raised OptimumBank Holdings' price target from $7.00 to $11.00, signaling a 15.24% potential upside. The bank shows strong financial health with a 2.04% ROAA, 20.34% ROAE, and a 4.57% net interest margin. Its loans grew...
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
